Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications
BN Rexer, CL Arteaga - Critical Reviews™ in Oncogenesis, 2012 - dl.begellhouse.com
Approximately 25% of human breast cancers overexpress the HER2 (ErbB2) proto-
oncogene, which confers a more aggressive tumor phenotype and associates with a poor …
oncogene, which confers a more aggressive tumor phenotype and associates with a poor …
[HTML][HTML] The mysterious ways of ErbB2/HER2 trafficking
V Bertelsen, E Stang - Membranes, 2014 - mdpi.com
The EGFR-or ErbB-family of receptor tyrosine kinases consists of EGFR/ErbB1,
ErbB2/HER2, ErbB3/HER3 and ErbB4/HER4. Receptor activation and downstream …
ErbB2/HER2, ErbB3/HER3 and ErbB4/HER4. Receptor activation and downstream …
[HTML][HTML] Computer-aided drug design in anti-cancer drug discovery: what have we learnt and what is the way forward??
The escalating prevalence of cancer on a global scale, coupled with the inadequacies of
present-day therapies and the emergence of drug-resistant cancer strains, has necessitated …
present-day therapies and the emergence of drug-resistant cancer strains, has necessitated …
[HTML][HTML] Nuclear functions and subcellular trafficking mechanisms of the epidermal growth factor receptor family
Accumulating evidence suggests that various diseases, including many types of cancer,
result from alteration of subcellular protein localization and compartmentalization. Therefore …
result from alteration of subcellular protein localization and compartmentalization. Therefore …
[HTML][HTML] ErbB1-4-dependent EGF/neuregulin signals and their cross talk in the central nervous system: pathological implications in schizophrenia and Parkinson's …
Ligands for ErbB1-4 receptor tyrosine kinases, such as epidermal growth factor (EGF) and
neuregulins, regulate brain development and function. Thus, abnormalities in their signaling …
neuregulins, regulate brain development and function. Thus, abnormalities in their signaling …
[HTML][HTML] Emerging promise of computational techniques in anti-cancer research: at a glance
MM Rahman, MR Islam, F Rahman, MS Rahaman… - Bioengineering, 2022 - mdpi.com
Research on the immune system and cancer has led to the development of new medicines
that enable the former to attack cancer cells. Drugs that specifically target and destroy …
that enable the former to attack cancer cells. Drugs that specifically target and destroy …
[HTML][HTML] An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models
W Xia, EF Petricoin, S Zhao, L Liu, T Osada… - Breast Cancer …, 2013 - Springer
Introduction The human epidermal growth factor receptor 2 (HER2) receptor tyrosine kinase
(RTK) oncogene is an attractive therapeutic target for the treatment of HER2-addicted …
(RTK) oncogene is an attractive therapeutic target for the treatment of HER2-addicted …
Receptor tyrosine kinases in the nucleus
G Carpenter, HJ Liao - Cold Spring Harbor perspectives …, 2013 - cshperspectives.cshlp.org
To date, 18 distinct receptor tyrosine kinases (RTKs) are reported to be trafficked from the
cell surface to the nucleus in response to ligand binding or heterologous agonist exposure …
cell surface to the nucleus in response to ligand binding or heterologous agonist exposure …
Proteolytic cleavage, trafficking, and functions of nuclear receptor tyrosine kinases
Intracellular localization has been reported for over three‐quarters of receptor tyrosine
kinase (RTK) families in response to environmental stimuli. Internalized RTK may bind to …
kinase (RTK) families in response to environmental stimuli. Internalized RTK may bind to …
[HTML][HTML] Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment
GS Herter-Sprie, H Greulich, KK Wong - Frontiers in oncology, 2013 - frontiersin.org
Despite the ongoing “war on cancer,” cancer remains one of the major causes of human
morbidity and mortality. A new paradigm of targeted therapies holds the most promise for the …
morbidity and mortality. A new paradigm of targeted therapies holds the most promise for the …